Physician Payment Sunshine Act New January 1, 2013 Compliance Deadline — Will You Be Ready?
Product Details
Rules implementing the Physician Payment Sunshine Act are bearing down on the drug and device industries. On May 2, CMS Acting Administrator Marilyn Tavenner stated that the final rule would be issued by the end of 2012 with implementation required 90 days after issuance date.
How bad is the forecast? If you can’t quickly and confidently answer the following questions, be prepared for up to $1,000,000 fines from CMS:
- When must drug/device companies perform retroactive reporting of payment information?
- What is the minimum payment that must be reported? And how do you value meals, trinkets and samples?
- Are you required to monitor payments or gifts to nurse practitioners, physician assistants and other non-MDs?
- The rules calls for tracking drug samples. But how detailed does the tracking have to be? Down to the blister pack? Vial? Tube?
- How do requirements differ for payments/gifts made to physicians conducting trials, versus those using medications and devices in their practice?
The final rule has been crafted with important transparency surrounding data collection and to address operational and implementation issues. And with hefty 'failure to comply' fines up to $1 million, it’s time to take this VERY seriously.
Don’t let the Sunshine Act turn into a black cloud and rain on you.
Listeners will get an in-depth look at what device and pharmaceutical companies need to learn now and how to participate and comply with the CMS Sunshine Act.
Just a few of the complexities you’ll need to master …
- When you must perform retroactive reporting of payment information.
- The minimum payments that must be reported.
- When you’re required to monitor payments or gifts to nurse practitioners, physician assistants and other non-MDs.
- New tracking restrictions that are being imposed on drug samples.
- How requirements differ for payments/gifts made to physicians, conducting trials, vs. those using medications and devices in their practices.
Please join Michaeline Daboul, President and CEO of MMIS, Inc., and Tim Robinson, Esq., the Executive Vice President and General Counsel for MMIS, Inc., for this 90-minute audio CD/transcript.
You will learn specifics being considered by the CMS, and gain real world knowledge from some companies with first-hand reporting experience. These companies know which rules are causing the most confusion and require more explanation.
Highlights you will learn at the webinar:
- How to identify ‘covered recipients.’
- How to proactively share information.
- How to compute your current aggregate spending.
- How to report quarterly basis disputes and resolutions, as they occur.
- How to understand the real-world implications of ‘aggregate’ spending.
- The best practices for sales people to ensure compliance.
- Industry standard portals – proven, tested results.
- How to quickly bring your business in compliance, by looking at proven and tested results.
Meet Your Instructors
Michaeline Daboul is the President and CEO of MMIS, Inc. Ms. Daboul is a veteran of the pharmaceutical industry, with over 25 years of experience working in genomics research, pharmaceutical drug development, and pharmaceutical marketing. She has lead organizations in the development of new technologies to create products and services for their Fortune 500 clients, and most recently, her innovative leadership has led to the development and implementation of collaborative enterprise platforms to enhance privacy and secure interactions between physicians, scientist, clinical researches and national experts. Ms. Daboul is a graduate of Rutgers University, where she received a B.S. in Biochemistry.
Tim Robinson, Esq., is the Executive Vice President & General Counsel for MMIS, Inc. Mr. Robinson started his law career in private practice, assisting entrepreneurial organizations with corporate formation, fund raising, and intellectual property law. Throughout the last 10 years, he has served as General Counsel for MMIS and has worked with numerous Fortune 500 companies to develop innovative products and services in the highly regulated healthcare and pharmaceutical industries. Recently, Mr. Robinson has been involved in the development and implementation of secure networks to facilitate collaboration among University researchers/scientists and industry professionals. Mr. Robinson is a graduate of the Boston University School of Law, where he received an LLM.